参考文献/References:
[1]马丽丽，付长江.存活素和细胞周期素依赖性蛋白激酶抑制因子2B在骨髓增生异常综合征诊断及患者预后评估中的临床价值研究[J].陕西医学杂志，2024，53(3)：348-351，356.[2]王美佳，刘虹伶，曾依伶.地西他滨联合HA方案治疗骨髓增生异常综合征疗效及安全性研究[J].陕西医学杂志，2023，52(12)：1731-1734.[3]DELLA PORTA M G，MALCOVATI L，STRUPP C，et al.Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome[J].Haematologica，2011，96(3)：441-449.[4]PRONK E，RAAIJMAKERS M.The mesenchymal niche in MDS[J].Blood，2019，133(10)：1031-1038.[5]STEENSMA D P，BEJAR R，JAISWAL S，et al.Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes[J].Blood，2015，126(1)：9-16.[6]ADRIANZEN HERRERA D，PRADHAN K，SNYDER R，et al.Myelodysplastic syndromes and the risk of cardiovascular disease in older adults：A SEER-medicare analysis[J].Leukemia，2020，34(6)：1689-1693.[7]MARNELL C S，BICK A，NATARAJAN P.Clonal hematopoiesis of indeterminate potential(CHIP)：Linking somatic mutations，hematopoiesis，chronic inflammation and cardiovascular disease[J].J Mol Cell Cardiol，2021，161：98-105.[8]GUMUSER E D，SCHUERMANS A，CHO S M J，et al.Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease[J].J Am Coll Cardiol，2023，81(20)：1996-2009.[9]VALENT P，HORNY H P，BENNETT J M，et al.Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes：Consensus statements and report from a working conference[J].Leuk Res，2007，31(6)：727-736.[10]LEVINE G N，BATES E R，BITTL J A，et al.2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease：A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J].J Am Coll Cardiol，2016，68(10)：1082-1115.[11]ARBER D A，ORAZI A，HASSERJIAN R，et al.The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia[J].Blood，2016，127(20)：2391-2405.[12]GREENBERG P L，TUECHLER H，SCHANZ J，et al.Revised international prognostic scoring system for myelodysplastic syndromes[J].Blood，2012，120(12)：2454-2465.[13]LIAPIS K，VRACHIOLIAS G，PAPADOPOULOS V，et al.Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes：A nationwide，registry-based cohort study[J].EJHaem，2020，1(1)：255-261.[14]AOKI H，SUZUKI Y，KANEKO H，et al.Myelodysplastic syndromes and incident cardiovascular disease：A nationwide，real-world cohort study[J].Can J Cardiol，2025，11：S0828-282X(25)01397-2 .[15]JAISWAL S，FONTANILLAS P，FLANNICK J，et al.Age-related clonal hematopoiesis associated with adverse outcomes[J].N Engl J Med，2014，371(26)：2488-2498.[16]HEYDE A，ROHDE D，MCALPINE C S，et al.Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis[J].Cell，2021，184(5)：1348-1361.e22.[17]ZEKAVAT S M，VIANA-HUETE V，MATESANZ N，et al.TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease[J].Nat Cardiovasc Res，2023，2：144-158.[18]FUSTER J J，MACLAUCHLAN S，ZURIAGA M A，et al.Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice[J].Science，2017，355(6327)：842-847.[19]BICK A G，WEINSTOCK J S，NANDAKUMAR S K，et al.Inherited causes of clonal haematopoiesis in 97691 whole genomes[J].Nature，2020，586(7831)：763-768.[20]POLLYEA D A，HARRIS C，RABE J L，et al.Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling[J].Haematologica，2019，104(9)：e388-e392.[21]TANG J，MA M，LIU F，et al.MiR-148a-3p mitigation of coronary artery disease through PCSK9/NF-κB inhibition of vascular endothelial cell injury[J].J Biochem Mol Toxicol，2024，38(11)：e70011.[22]POLLYEA D A，KIM H M，STEVENS B M，et al.MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells[J].J Leukoc Biol，2021，110(1)：197-205.[23]SIMARD J C，CESARO A，CHAPETON-MONTES J，et al.S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB(1.)[J].PLoS One，2013，8(8)：e72138.[24]DINARELLO C A.A clinical perspective of IL-1β as the gatekeeper of inflammation[J].Eur J Immunol，2011，41(5)：1203-1217.[25]CASTELLI R，SCHIAVON R，ROSSI V，et al.Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents[J].Med Oncol，2018，35(5)：76.[26]OREN O，SMALL A M，LIN A E，et al.Managing cardiovascular risk in clonal hematopoiesis of indeterminate potential：JACC cardiooncology short-form primer[J].JACC Cardio Oncol，2025，7(5)：496-500.[27]RIDKER P M，EVERETT B M，THUREN T，et al.Antiinflammatory therapy with canakinumab for atherosclerotic disease[J].N Engl J Med，2017，377(12)：1119-1131.[28]SCHNEIDER M，ROLFS C，TRUMPP M，et al.Activation of distinct inflammatory pathways in subgroups of LR-MDS[J].Leukemia，2023，37(8)：1709-1718.
相似文献/References:
[1]聂泽强,李晓云,马爻芳,等.WT1基因在骨髓增生异常综合征患者外同血中的表达及临床意义[J].陕西医学杂志,2019,(8):977.
NIE Zeqiang,LI Xiaoyun,MA Yaofang,et al.Expression of WT1 gene in patients with Myelodysplastic syndrome[J].,2019,(6):977.
[2]董 曼,王月莉.不同剂量地西他滨对骨髓增生异常综合征小鼠Beclin1蛋白表达的影响[J].陕西医学杂志,2021,50(6):657.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
DONG Man,WANG Yueli.Effects of different doses of decitabine on Beclin1 protein expression in mice with myelodysplastic syndrome[J].,2021,50(6):657.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
[3]李振波,陆 诚.阿扎胞苷治疗骨髓增生异常综合征合并额外性梳样蛋白1基因突变疗效及安全性分析[J].陕西医学杂志,2021,50(9):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
LI Zhenbo,LU Cheng.Efficacy and safety of azacitidine in treatment of MDS with ASXL1 gene mutation[J].,2021,50(6):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
[4]李荣芳,金 龙,赵立丹.外周血T细胞免疫球蛋白黏蛋白-3和血清乳酸脱氢酶联合检测在骨髓增生异常综合征诊断中的应用价值[J].陕西医学杂志,2021,50(9):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
LI Rongfang,JIN Long,ZHAO Lidan.Application value of combined detection of peripheral blood TIM-3 and serum LDH in diagnosis of MDS[J].,2021,50(6):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
[5]王美佳,刘虹伶,曾依伶.地西他滨联合HA方案治疗骨髓增生异常综合征疗效及安全性研究[J].陕西医学杂志,2023,52(12):1731.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
WANG Meijia,LIU Hongling,ZENG Yiling.Efficacy and safety of decitabine combined with harringtonine and cytarabine regimen in treatment of myelodysplastic syndrome[J].,2023,52(6):1731.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
[6]马丽丽,付长江.存活素和细胞周期素依赖性蛋白激酶抑制因子2B在骨髓增生异常综合征诊断及患者预后评估中的临床价值研究[J].陕西医学杂志,2024,(3):348.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]
MA Lili,FU Changjiang.Clinical value of Survivin and P15INK4B in diagnosis of myelodysplastic syndrome and prognosis evaluation of patients[J].,2024,(6):348.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]